Incidence of finding residual disease for incidental gallbladder carcinoma: Implications for re-resection

被引:282
作者
Pawlik, Timothy M.
Gleisner, Ana Luiza
Vigano, Luca
Kooby, David A.
Bauer, Todd W.
Frilling, Andrea
Adams, Reid B.
Staley, Charles A.
Trindade, Eduardo N.
Schulick, Richard D.
Choti, Michael A.
Capussotti, Lorenzo
机构
[1] Johns Hopkins Univ, Dept Surg, Sch Med, Baltimore, MD USA
[2] Univ Fed Rio Grande do Sul, Dept Surg, Porto Alegre, RS, Brazil
[3] Univ Hosp Essen, Dept Surg, Essen, Germany
[4] Inst Res Cure Canc, Dept Surg, Candiolo, Italy
[5] Emory Univ, Sch Med, Dept Surg, Atlanta, GA USA
[6] Univ Virginia, Med Ctr, Dept Surg, Charlottesville, VA USA
关键词
gallbladder carcinoma; incidental; resection; residual disease; common bile duct;
D O I
10.1007/s11605-007-0309-6
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Re-resection for gallbladder carcinoma incidentally discovered after cholecystectomy is routinely advocated. However, the incidence of finding additional disease at the time of re-resection remains poorly defined. Between 1984 and 2006, 115 patients underwent re-resection at six major hepatobiliary centers for gallbladder carcinoma incidentally discovered during cholecystectomy. Data on clinicopathologic factors, operative details, TNM tumor stage, and outcome were collected and analyzed. Data on the incidence and location of residual/additional carcinoma discovered at the time of re-resection were also recorded. On pathologic analysis, T stage was T1 7.8%, T2 67.0%, and T3 25.2%. The median time from cholecystectomy to re-resection was 52 days. At the time of re-resection, hepatic surgery most often consisted of formal segmentectomy (64.9%). Patients underwent lymphadenectomy (LND) (50.5%) or LND + common bile duct resection (43.3%). The median number of lymph nodes harvested was 3 and did not differ between LND alone (n=3) vs LND + common duct resection (n=3) (P=0.35). Pathology from the re-resection specimen noted residual/additional disease in 46.4% of patients. Of those patients staged as T1, T2, or T3, 0, 10.4, and 36.4%, respectively, had residual disease within the liver (P=0.01). T stage was also associated with the risk of metastasis to locoregional lymph nodes (lymph node metastasis: T1 12.5%; T2 31.3%, T3 45.5%; P= 0.04). Cystic duct margin status predicted residual disease in the common bile duct (negative cystic duct, 4.3% vs positive cystic duct, 42.1%) (P=0.01). Aggressivere-resection for incidental gallbladder carcinoma is warranted as the majority of patients have residual disease. Although common duct resection does not yield a greater lymph node count, it should be performed at the time of re-resection for patients with positive cystic duct margins because over one-third will have residual disease in the common bile duct.
引用
收藏
页码:1478 / 1486
页数:9
相关论文
共 35 条
[1]
Long-term results after resection for gallbladder cancer - Implications for staging and management [J].
Bartlett, DL ;
Fong, YM ;
Fortner, JG ;
Brennan, MF ;
Blumgart, LH .
ANNALS OF SURGERY, 1996, 224 (05) :639-646
[2]
Long-term results after curative resection for carcinoma of the gallbladder [J].
Benoist, S ;
Panis, Y ;
Fagniez, PL .
AMERICAN JOURNAL OF SURGERY, 1998, 175 (02) :118-122
[3]
Role of surgery for gallbladder carcinoma with special reference to lymph node metastasis and stage using Western and Japanese classification systems [J].
Chijiiwa, K ;
Noshiro, H ;
Nakano, K ;
Okido, M ;
Sugitani, A ;
Yamaguchi, K ;
Tanaka, M .
WORLD JOURNAL OF SURGERY, 2000, 24 (10) :1271-1277
[4]
CHIJIIWA K, 1994, SURGERY, V115, P751
[5]
Surgical treatment of patients with T2 gallbladder carcinoma invading the subserosal layer [J].
Chijiiwa, K ;
Nakano, K ;
Ueda, J ;
Nishiro, H ;
Nagai, E ;
Yamaguchi, K ;
Tanaka, M .
JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS, 2001, 192 (05) :600-607
[6]
Chijiiwa K, 1996, EUR J SURG, V162, P211
[7]
SURGICAL-TREATMENT OF 724 CARCINOMAS OF THE GALLBLADDER - RESULTS OF THE FRENCH-SURGICAL-ASSOCIATION SURVEY [J].
CUBERTAFOND, P ;
GAINANT, A ;
CUCCHIARO, G .
ANNALS OF SURGERY, 1994, 219 (03) :275-280
[8]
DONOHUE JH, 1990, ARCH SURG-CHICAGO, V125, P237
[9]
Fong Y, 1998, CANCER-AM CANCER SOC, V83, P423, DOI 10.1002/(SICI)1097-0142(19980801)83:3<423::AID-CNCR9>3.0.CO
[10]
2-P